Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework

Statistical Methods for Rates and Proportions

Fleiss, J. L., Levin, B., & Paik, M. C. (2003) · Wiley Series in Probability and Statistics · doi:10.1002/0471445428 · Cited by 18,646 · see citing works

Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials

Ronco, G., Dillner, J., Elfström, K. M., Tunesi, S., Snijders, P. J. F., Arbyn, M., Kitchener, H., Segnan, N., Gilham, C., Giorgi-Rossi, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62218-7 · Cited by 1,810 · see citing works

Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial

Ronco, G., Rossi, P. G., Carozzi, F., Confortini, M., Palma, P. D., Mistro, A. D., Ghiringhello, B., Girlando, S., Gillio‐Tos, A., Marco, L. D., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70360-2 · Cited by 935 · see citing works

Evidence Regarding Human Papillomavirus Testing in Secondary Prevention of Cervical Cancer

Arbyn, M., Ronco, G., Anttila, A., Meijer, C. J. L. M., Poljak, M., Ogilvie, G., Koliopoulos, G., Naucler, P., Sankaranarayanan, R., & Peto, J. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.06.095 · Cited by 897 · see citing works

Human Papillomavirus and Papanicolaou Tests to Screen for Cervical Cancer

Nauclér, P., Ryd, W., Törnberg, S., Strand, A., Wadell, G., Elfgren, K., Rådberg, T., Strander, B., Johansson, B., Forslund, O., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073204 · Cited by 797 · see citing works

Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older

Meijer, C. J. L. M., Berkhof, J., Castle, P. E., Hesselink, A. T., Franco, E. L., Ronco, G., Arbyn, M., Bosch, F. X., Cuzick, J., Dillner, J., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24010 · Cited by 692 · see citing works

Overview of Human Papillomavirus-Based and Other Novel Options for Cervical Cancer Screening in Developed and Developing Countries

Cuzick, J. M., Arbyn, M., Sankaranarayanan, R., Tsu, V. D., Ronco, G., Mayrand, M., Dillner, J., & Meijer, C. J. L. M. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.06.019 · Cited by 637 · see citing works

Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial

Bulkmans, N. W. J., Berkhof, J. H., Rozendaal, L., van Kemenade, F. J., Boeke, A. J. P., Bulk, S., Voorhorst, F. J., Verheijen, R. H. M., van Groningen, K., Boon, M. E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61450-0 · Cited by 636 · see citing works

Primary cervical cancer screening with human papillomavirus: End of study results from the ATHENA study using HPV as the first-line screening test

Wright, T. C., Stoler, M. H., Behrens, C. M., Sharma, A., Zhang, G., & Wright, T. L. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.11.076 · Cited by 601 · see citing works

Chapter 9: Clinical applications of HPV testing: A summary of meta-analyses

Arbyn, M., Sasieni, P. D., Meijer, C. J. L. M., Clavel, C., Koliopoulos, G., & Dillner, J. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.117 · Cited by 539 · see citing works

Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study

Castle, P. E., Stoler, M. H., Wright, T. C., Sharma, A., Wright, T. L., & Behrens, C. M. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70188-7 · Cited by 526 · see citing works

HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial

Kitchener, H. C., Almonte, M., Thomson, C., Wheeler, P., Sargent, A., Stoykova, B., Gilham, C., Baysson, H., Roberts, C., Dowie, R., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70156-1 · Cited by 390 · see citing works

High-Risk Human Papillomavirus Testing in Women With ASC-US Cytology

Stoler, M. H., Wright, T. C., Sharma, A., Apple, R. J., Gutekunst, K. A., & Wright, T. L. (2011) · American Journal of Clinical Pathology · doi:10.1309/ajcpz5jy6fcvnmot · Cited by 327 · see citing works

Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?

Arbyn, M., Snijders, P. J. F., Meijer, C. J. L. M., Berkhof, J., Cuschieri, K., Kocjan, B. J., & Poljak, M. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.04.015 · Cited by 275 · see citing works

Reassurance Against Future Risk of Precancer and Cancer Conferred by a Negative Human Papillomavirus Test

Gage, J. C., SCHIFFMAN, M. H., Katki, H. A., Castle, P., Fetterman, B. J., Wentzensen, N., Poitras, N. E., Lorey, T. S., Cheung, L. C., & Kinney, W. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju153 · Cited by 260 · see citing works

Status of implementation and organization of cancer screening in The European Union Member States—Summary results from the second European screening report

Basu, P. S., Ponti, A., Anttila, A., Ronco, G., Senore, C., Vale, D. B., Segnan, N., Tomatis, M., Soerjomataram, I., Žakelj, M. P., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.31043 · Cited by 252 · see citing works

Evaluation of HPV-16 and HPV-18 Genotyping for the Triage of Women With High-Risk HPV+ Cytology-Negative Results

Wright, T. C., Stoler, M. H., Sharma, A., Zhang, G., Behrens, C. M., & Wright, T. L. (2011) · American Journal of Clinical Pathology · doi:10.1309/ajcptus5exas6dkz · Cited by 225 · see citing works

Comparing the performance of six human papillomavirus tests in a screening population

Cuzick, J., Cadman, L., Mesher, D., Austin, J., Ashdown-Barr, L., Ho, L., Terry, G., Liddle, S., Wright, C., Lyons, D., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.22 · Cited by 211 · see citing works

Evaluation of 14 triage strategies for HPV DNA‐positive women in population‐based cervical screening

Rijkaart, D., Berkhof, J. H., van Kemenade, F. J., Coupé, V. M. H., Hesselink, A. T., Rozendaal, L., Heideman, D. A. M., Verheijen, R. H., Bulk, S., Verweij, W. M., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26056 · Cited by 205 · see citing works

Clinical Validation of the cobas 4800 HPV Test for Cervical Screening Purposes

Heideman, D. A. M., Hesselink, A. T., Berkhof, J. H., van Kemenade, F. J., Melchers, W. J. G., Daalmeijer, N. F., Verkuijten, M. C. G. T., Meijer, C. J. L. M., & Snijders, P. J. F. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.05552-11 · Cited by 201 · see citing works

VALGENT: a protocol for clinical validation of human papillomavirus assays

Arbyn, M., Depuydt, C., Benoy, I., Bogers, J., Cuschieri, K., Schmitt, M., Pawlita, M., Geraets, D., Heard, I., Gheit, T., et al. (2016) · Journal of Clinical Virology · doi:10.1016/j.jcv.2015.09.014 · Cited by 157 · see citing works

Multiple Human Papillomavirus Infections with High Viral Loads Are Associated with Cervical Lesions but Do Not Differentiate Grades of Cervical Abnormalities

Schmitt, M., Depuydt, C., Benoy, I. H., Bogers, J., Antoine, J., Arbyn, M., & Pawlita, M. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.00087-13 · Cited by 148 · see citing works

Commercially available molecular tests for human papillomaviruses (HPV): 2015 update

Poljak, M., Kocjan, B. J., Oštrbenk, A., & Seme, K. (2015) · Journal of Clinical Virology · doi:10.1016/j.jcv.2015.10.023 · Cited by 126 · see citing works

History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results

Cox, J. T. (2009) · Journal of Clinical Virology · doi:10.1016/s1386-6532(09)70002-2 · Cited by 76 · see citing works

Comparison of Clinical and Analytical Performance of the Abbott RealTime High Risk HPV Test to the Performance of Hybrid Capture 2 in Population-Based Cervical Cancer Screening

Poljak, M., Oštrbenk, A., Seme, K., Učakar, V., Hillemanns, P., Bokal, E. V., Jančar, N., & Klavs, I. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00012-11 · Cited by 74 · see citing works

Need for expanded HPV genotyping for cervical screening

Cuzick, J. M., & Wheeler, C. M. (2016) · Papillomavirus Research · doi:10.1016/j.pvr.2016.05.004 · Cited by 73 · see citing works

The role of human papillomavirus testing in cervical screening

Cuschieri, K. S., & Cubie, H. (2005) · Journal of Clinical Virology · doi:10.1016/j.jcv.2004.11.020 · Cited by 66 · see citing works

Clinical validation of Anyplex™ II HPV HR Detection according to the guidelines for HPV test requirements for cervical cancer screening

Hesselink, A. T., Sahli, R., Berkhof, J., Snijders, P. J. F., van der Salm, M. L., Agard, D., Bleeker, M. C. G., & Heideman, D. A. M. (2016) · Journal of Clinical Virology · doi:10.1016/j.jcv.2016.01.009 · Cited by 61 · cited 4× · see citing works

Clinical and Analytical Performance of the Onclarity HPV Assay Using the VALGENT Framework

Cuschieri, K. S., Geraets, D. T., Moore, C., Quint, W. G. V., Duvall, E., & Arbyn, M. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.01366-15 · Cited by 59 · see citing works

Prevalence and viral load of 51 genital human papillomavirus types and three subtypes

Schmitt, M., Depuydt, C., Benoy, I. H., Bogers, J., Antoine, J., Arbyn, M., Pawlita, M., & on behalf of the VALGENT Study Group (2012) · International Journal of Cancer · doi:10.1002/ijc.27891 · Cited by 59 · see citing works

Comparison of the anyplex II HPV28 assay with the hybrid capture 2 assay for the detection of HPV infection

Kwon, M.-J., Roh, K. H., Park, H., & Woo, H.-Y. (2014) · Journal of Clinical Virology · doi:10.1016/j.jcv.2014.01.015 · Cited by 55 · see citing works

Performance of a Cartridge-Based Assay for Detection of Clinically Significant Human Papillomavirus (HPV) Infection: Lessons from VALGENT (Validation of HPV Genotyping Tests)

Cuschieri, K., Geraets, D., Cuzick, J., Cadman, L., Moore, C., Vanden Broeck, D., Padalko, E., Quint, W., & Arbyn, M. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.00897-16 · Cited by 55 · see citing works

Human Papillomavirus Oncogenic mRNA Testing for Cervical Cancer Screening

Reid, J. L., Wright, T. C., Stoler, M. H., Cuzick, J. M., Castle, P. E., Dockter, J., Getman, D., & Giachetti, C. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcphvd7mip3fyvv · Cited by 55 · see citing works

Viral Load of High-Risk Human Papillomaviruses as Reliable Clinical Predictor for the Presence of Cervical Lesions

Schmitt, M., Depuydt, C., Benoy, I. H., Bogers, J., Antoine, J., Pawlita, M., & Arbyn, M. (2013) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-12-1067 · Cited by 52 · see citing works

Human papillomavirus and Papanicolaou tests screening interval recommendations in the United States

Roland, K. B., Soman, A. V., Benard, V. B., & Saraiya, M. (2011) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2011.06.001 · Cited by 48 · see citing works

Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework

Xu, L., Oštrbenk, A., Poljak, M., & Arbyn, M. (2018) · Journal of Clinical Virology · doi:10.1016/j.jcv.2017.12.001 · Cited by 45 · see citing works

Clinical Evaluation of a GP5+/6+-Based Luminex Assay Having Full High-Risk Human Papillomavirus Genotyping Capability and an Internal Control

Geraets, D. T., Cuschieri, K. S., de Koning, M. N. C., Doorn, L. J. V., Snijders, P. J. F., Meijer, C. J. L. M., Quint, W. G. V., & Arbyn, M. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.01962-14 · Cited by 43 · see citing works

HPV Testing by cobas HPV Test in a Population from Catalonia

Lloveras, B., Gomez, S., Alameda, F., Bellosillo, B., Mojal, S., Muset, M., Parra, M., Palomares, J. C., & Serrano, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058153 · Cited by 36 · see citing works

Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel

Polman, N. J., Oštrbenk, A., Xu, L., Snijders, P. J. F., Meijer, C. J. L. M., Poljak, M., Heideman, D. A. M., & Arbyn, M. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.01282-17 · Cited by 33 · see citing works

Clinical Validation of Anyplex II HPV HR Detection Test for Cervical Cancer Screening in Korea

Jung, S., Lee, B., Lee, K. N., Kim, Y., & Oh, E.-J. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2015-0117-oa · Cited by 33 · see citing works

On the cross-fertilization between biotechnology and immunology: current situation in Cuba

Lage, A. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.01.101 · Cited by 29 · see citing works

Clinical and analytical performance of the PapilloCheck HPV-Screening assay using the VALGENT framework

Heard, I., Cuschieri, K. S., Geraets, D. T., Quint, W. G. V., & Arbyn, M. (2016) · Journal of Clinical Virology · doi:10.1016/j.jcv.2016.05.004 · Cited by 29 · see citing works

Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention

Barzon, L., Giorgi, C., Buonaguro, L., Palù, G., & the Italian Society for Virology (2008) · Infectious Agents and Cancer · doi:10.1186/1750-9378-3-14 · Cited by 26 · see citing works

Primary human papillomavirus DNA screening for cervical cancer prevention: Can the screening interval be safely extended?

Vink, M. A., Bogaards, J. A., Meijer, C. J. L. M., & Berkhof, J. H. (2014) · International Journal of Cancer · doi:10.1002/ijc.29381 · Cited by 24 · see citing works

Anyplex II HPV28 detection and Anyplex II HPV HR detection assays are highly concordant with other commercial assays for detection of high-risk HPV genotypes in women with high grade cervical abnormalities

Cornall, A. M., Poljak, M., Garland, S. M., Phillips, S., Tan, J. H., Machalek, D. A., Quinn, M. A., & Tabrizi, S. N. (2017) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-016-2831-5 · Cited by 22 · see citing works

Comparison of the performance of Anyplex II HPV HR, the Cobas 4800 human papillomavirus test and Hybrid Capture 2

Lee, D.-H., Hwang, N. R., Lim, M. C., Yoo, C. W., Joo, J., Kim, J., Park, S., & Hwang, S. (2015) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563215614036 · Cited by 22 · see citing works

The HPV test in cervical screening: a brave new world?

Desai, M., & Cubie, H. (2005) · Cytopathology · doi:10.1111/j.1365-2303.2005.00237.x · Cited by 13 · see citing works

2020 list of human papillomavirus assays suitable for primary cervical cancer screening

Arbyn, M., Simon, M., Peeters, E., Xu, L., Meijer, C. J. L. M., Berkhof, J., Cuschieri, K., Bonde, J., Ostrbenk Vanlencak, A., Zhao, F.-H., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.04.031 · Cited by 284 · see citing works

Clinical and Analytical Performance of the BD Onclarity HPV Assay with SurePath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework

Bonde, J. H., Pedersen, H., Quint, W., Xu, L., Arbyn, M., & Ejegod, D. M. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.01518-19 · Cited by 37 · see citing works

Clinical performance of Anyplex II HPV28 by human papillomavirus type and viral load in a referral population.

Baasland, I., Romundstad, P. R., Eide, M. L., & Jonassen, C. M. (2019) · PLOS ONE · doi:10.1371/journal.pone.0210997 · Cited by 33 · see citing works

hrHPV prevalence and type distribution in rural Zimbabwe: A community-based self-collection study using near-point-of-care GeneXpert HPV testing

Fitzpatrick, M. B., Mandishora, R. S. D., Katzenstein, D. A., McCarty, K., Weber, J., Sahoo, M. K., Manasa, J., Chirenje, Z. M., & Pinsky, B. A. (2019) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2019.02.022 · Cited by 27 · see citing works

Alinity m HR HPV Assay Fulfills Criteria for Human Papillomavirus Test Requirements in Cervical Cancer Screening Settings

Oštrbenk, A., Šterbenc, A., Seme, K., & Poljak, M. (2019) · Journal of Clinical Microbiology · doi:10.1128/jcm.01120-19 · Cited by 26 · see citing works

Characterization and Diversity of 243 Complete Human Papillomavirus Genomes in Cervical Swabs Using Next Generation Sequencing

Latsuzbaia, A., Wienecke-Baldacchino, A. K., Tapp, J., Arbyn, M., Karabegović, I., Chen, Z., Fischer, M., Mühlschlegel, F., Weyers, S., Pesch, P., et al. (2020) · Viruses · doi:10.3390/v12121437 · Cited by 24 · see citing works

Comparison between the Roche Cobas 4800 Human Papillomavirus (HPV), Abbott RealTime High-Risk HPV, Seegene Anyplex II HPV28, and Novel Seegene Allplex HPV28 Assays for High-Risk HPV Detection and Genotyping in Mocked Self-Samples

Bell, M., Verberckmoes, B., Devolder, J., Vermandere, H., Degomme, O., Guimarães, Y. M., Godoy, L. R., Ambrosino, E., Cools, P., & Padalko, E. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.00081-23 · Cited by 22 · see citing works

Evaluation of Human Papilloma Virus (HPV) Genotyping and Viral Load Determination as Diagnostic Biomarkers of Cervical Cancer Risk

Martinelli, M., Giubbi, C., Saderi, L., Musumeci, R., Perdoni, F., Leone, B. E., Fruscio, R., Landoni, F., Piana, A. F., Sotgiu, G., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021320 · Cited by 21 · see citing works

Using the VALGENT-3 framework to assess the clinical and analytical performance of the RIATOL qPCR HPV genotyping assay

Benoy, I. H., Xu, L., Broeck, D. V., Poljak, M., Oštrbenk, A., Arbyn, M., & Bogers, J. (2019) · Journal of Clinical Virology · doi:10.1016/j.jcv.2019.09.008 · Cited by 21 · see citing works

Allplex HPV HR Detection assay fulfils all clinical performance and reproducibility validation requirements for primary cervical cancer screening

Oštrbenk Valenčak, A., Cuschieri, K., Connor, L., Zore, A., Smrkolj, Š., & Poljak, M. (2024) · Journal of Clinical Virology · doi:10.1016/j.jcv.2023.105638 · Cited by 20 · see citing works

Evaluation and Optimization of the Clinical Accuracy of Hybribio's 14 High-Risk HPV with 16/18 Genotyping Assay within the VALGENT-3 Framework

Xu, L., Oštrbenk, A., Poljak, M., & Arbyn, M. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.00234-20 · Cited by 16 · see citing works

Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework

Ejegod, D. M., Hansen, M., Christiansen, I. K., Pedersen, H., Quint, W. G. V., Xu, L., Arbyn, M., & Bonde, J. H. (2020) · Journal of Clinical Virology · doi:10.1016/j.jcv.2020.104336 · Cited by 16 · see citing works

Accuracy of genotyping for HPV16 and 18 to triage women with low-grade squamous intraepithelial lesions: a pooled analysis of VALGENT studies

Xu, L., Benoy, I. H., Cuschieri, K. S., Poljak, M., Bonde, J. H., & Arbyn, M. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1613890 · Cited by 15 · see citing works

Human Papillomavirus genotype concordance between Anyplex II HPV28 and Linear array HPV genotyping test in anogenital samples

Coutlée, F., de Pokomandy, A., Burchell, A. N., El‐Zein, M., Mayrand, M., Rodrigues‐Coutlée, S., Money, D., Comète, É., McClymont, E., Rouleau, D., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27605 · Cited by 15 · see citing works

Hookworm infection associates with a vaginal Type 1/Type 2 immune signature and increased HPV load

Omondi, M. A., Kamassa, H. E., Katawa, G., Tchopba, C. N., Vogelbusch, C., Parčina, M., Tchadié, P. E., Amessoudji, M. O., Arndts, K., Karou, S. D., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1009968 · Cited by 13 · see citing works

A comparison of high‐risk human papillomavirus DNA detection between urine and cervical sample testing in women with abnormal Pap smears

Punyashthira, A., Horthongkham, N., Jaishuen, A., Jareemit, N., & Achariyapota, V. (2021) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.15095 · Cited by 9 · see citing works

Comparison of the clinical and analytical performance of Alinity m HR HPV and cobas 4800 HPV assays in a population-based screening setting

Oštrbenk, A., Bertram, A., Gröning, A., & Poljak, M. (2021) · Journal of Clinical Virology · doi:10.1016/j.jcv.2021.104851 · Cited by 8 · see citing works

Optimization and analytical validation of the Allplex HPV28 genotyping assay for use in first-void urine samples

Bell, M., Baussano, I., Rol, M., Tenet, V., Heideman, D. A. M., Gheit, T., Caesbroeck, A. V., Vorsters, A., & Clifford, G. M. (2024) · Journal of Clinical Microbiology · doi:10.1128/jcm.01404-24 · Cited by 8 · see citing works

Distribución de genotipos de virus papiloma humano de alto riesgo en mujeres y hombres atendidos en una red asistencial privada en la Región Metropolitana, Chile

Tapia, C. I., Campos, M., Pozas, N., Sarda, A. G., & Walker, K. (2024) · Revista chilena de infectología · doi:10.4067/s0716-10182024000100020 · Cited by 7 · see citing works

Detección y genotipificación del virus del papiloma humano de alto riesgo mediante PCR multiplex en tiempo real (RT-PCR VPH AR)

Mesa-Arango, J. A., Tapia, L., Loaiza-Díaz, N., Echeverry-Chica, J., & Toro-Montoya, A. I. (2021) · Medicina y Laboratorio · doi:10.36384/01232576.439 · Cited by 7 · see citing works

Concordance of Anyplex™ II HPV HR assays with reference HPV assays in cervical cancer screening: Systematic review

Biazin, H. (2022) · Journal of Virological Methods · doi:10.1016/j.jviromet.2021.114435 · Cited by 5 · see citing works

Comparative performance of cobas 4800 HPV Test and Anyplex II HPV HR for high-risk human papillomavirus detection

Godoy, L. R., El-Zein, M., Padalko, E. Y., Verberckmoes, B., Eenooghe, B. V., Vermandere, H., Dias, S., Gama, A., Vega, B., Neira, V. A., et al. (2025) · Journal of Clinical Microbiology · doi:10.1128/jcm.00200-25 · Cited by 5 · see citing works

Evaluation of HarmoniaHPV test for detection of clinically significant Human Papillomavirus infection using the VALGENT framework

Bhatia, R., Boada, E. A., Bonde, J. H., Quint, W. G. V., Christiansen, I. K., Xu, L., Ejegod, D. M., Moncur, S., Cuschieri, K. S., & Arbyn, M. (2021) · Journal of Virological Methods · doi:10.1016/j.jviromet.2021.114161 · Cited by 5 · see citing works

Papilloplex HR-HPV test has non-inferior clinical performance for detection of human papillomavirus infection: assessment using the VALGENT framework

Bhatia, R., Boada, E. A., Bonde, J. H., Quint, W. G. V., Xu, L., Ejegod, D. M., Cuschieri, K. S., & Arbyn, M. (2021) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2021-207864 · Cited by 3 · see citing works

The Key Role of Mathematical Modeling and Health Economics in the Public Health Transitions in Cervical Cancer Prevention

Canfell, K., & Berkhof, J. H. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814457-2.00020-9 · Cited by 3 · see citing works

Anyplex II HPV test in detection and follow‐up after surgical treatment of CIN2+ lesions

Bottari, F., Iacobone, A. D., Radice, D., Preti, E. P., Preti, M., Franchi, D., Piana, A. F., Sandri, M. T., & Passerini, R. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26862 · Cited by 2 · see citing works

Clinical Performance of the Full Genotyping Agena MassARRAY HPV Assay Using SurePath Screening Samples within the VALGENT4 Framework

Pedersen, H., Ejegod, D. M., Quint, W. G. V., Xu, L., Arbyn, M., & Bonde, J. H. (2022) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2021.12.009 · Cited by 2 · see citing works

Clinical and analytical performance of the CLART HPV 4S assay with SurePath screening samples from the Danish cervical cancer screening program using the VALGENT framework

Ejegod, D. M., Pedersen, H., Quint, W. G. V., Xu, L., Arbyn, M., & Bonde, J. H. (2021) · Journal of Virological Methods · doi:10.1016/j.jviromet.2021.114118 · Cited by 2 · see citing works

Comparative analysis of SD biosensor standard™ M10 HPV and seegene anyplex™ II HPV HR for detecting high-risk human papillomavirus: a concordance study

Jerip, A. R., Noni, V., Anthony, V. K., Bong, A. C. S., Adam, J., & Tan, C. S. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-10714-y · Cited by 1 · see citing works

E6/E7 Similarity to Human Papillomavirus Prototypes and Performance of HPV Testing by Cobas 4800 HPV Test and Anyplex II HPV HR

Godoy, L. R., El‐Zein, M., Cools, P., Padalko, E. Y., Verberckmoes, B., Degomme, O., Vermandere, H., Mühr, L. S. A., Stosic, M. S., Franco, E. L., et al. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70668

Persistently high prevalence of HPV16 and rising prevalence of non-16/18 HR-HPV genotypes in cervical precancer and cancer in Latvia in 2016-2024 shape the severity of cervical disease

Sokolovska, L., Biserova, K., Spridzāne, A., Krišāne, D., Dudorova, A., Gebrila, S., Krasovska, I., Perminov, D., Orlova, B., Petrovska, M., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1676334

Head‐to‐head comparison of the MyGen e human papillomavirus–sexually transmitted infection assay versus the Cobas 4800 human papillomavirus test for detecting high‐grade cervical intraepithelial neoplasia

Zhou, H., Zhang, H., Pi, R., Yang, Y., Li, T., Chen, S., Chen, Y., Dai, Y., Zhu, H., Zhao, Y., et al. (2026) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.70869

Human papillomavirus viral load as promising surrogate biomarker of cervical cancer risk and clinical outcome

Bouassa, R. M., Tukisadila, J. M., Loemba, H., & Bélec, L. (2026) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2026.2675388

Eficacia y coste-efectividad de incluir el genotipado de VPH en el cribado de cáncer de cérvix

Gutiérrez-Pizarraya, A., Márquez, J. M. M., López, R. R., Blasco‐Amaro, J. A., Sánchez, F. J., García-Agua-Soler, N., González-Álvarez, M. L., & García-Ruiz, A. J. (2026) · doi:10.52766/nwdq7431

Comparison of the performance of Anyplex II HPV HR, the Cobas 4800 human papillomavirus test and Hybrid Capture 2

Lee, D.-H., Hwang, N. R., Lim, M. C., Yoo, C. W., Joo, J., Kim, J., Park, S., & Hwang, S. (2015) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563215614036 · Cited by 22 · see citing works

Comparison of Cobas® HPV and Anyplex™ II HPV28 assays for detecting and genotyping human papillomavirus

Pasquier, C., Sauné, K., Raymond, S., Boisneau, J., Courtade, M., & Izopet, J. (2017) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2016.08.022 · Cited by 9 · see citing works

Comparison of the anyplex II HPV28 assay with the hybrid capture 2 assay for the detection of HPV infection

Kwon, M.-J., Roh, K. H., Park, H., & Woo, H.-Y. (2014) · Journal of Clinical Virology · doi:10.1016/j.jcv.2014.01.015 · Cited by 55 · see citing works

Comparative performance of cobas 4800 HPV Test and Anyplex II HPV HR for high-risk human papillomavirus detection

Godoy, L. R., El-Zein, M., Padalko, E. Y., Verberckmoes, B., Eenooghe, B. V., Vermandere, H., Dias, S., Gama, A., Vega, B., Neira, V. A., et al. (2025) · Journal of Clinical Microbiology · doi:10.1128/jcm.00200-25 · Cited by 5 · see citing works

Performance evaluation of Anyplex™II HPV28 detection kit in a routine diagnostic setting: Comparison with the HPV Sign® Genotyping Test

Marcuccilli, F., Farchi, F., Mirandola, W., Ciccozzi, M., Paba, P., Bonanno, E., Perno, C. F., & Ciotti, M. (2015) · Journal of Virological Methods · doi:10.1016/j.jviromet.2015.02.018 · Cited by 15 · see citing works